Form 4: Evoke Pharma CMO Sells Shares Post-Merger

Evoke Pharma's Chief Medical Officer reported the disposition of common stock and cash-out of stock options following the company's acquisition by QOL Medical.

Summary

• Marilyn R. Carlson, Chief Medical Officer of Evoke Pharma Inc. (EVOK), reported changes in her beneficial ownership of company securities.
• The changes are a direct result of the Agreement and Plan of Merger, dated November 3, 2025, between Evoke Pharma, QOL Medical, LLC ("Parent"), and QOL-EOS Merger Sub, Inc. ("Merger Sub").
• On December 16, 2025, a tender offer was completed, where Parent and Merger Sub acquired all outstanding shares of Evoke Pharma Common Stock for $11.00 per share in cash.
• Effective December 17, 2025, Merger Sub merged into Evoke Pharma, making Evoke Pharma a wholly-owned subsidiary of Parent.
• Marilyn R. Carlson disposed of 360 shares of Common Stock.
• Her outstanding stock options, including 17,291 shares with an exercise price of $5.27 and 11,000 shares with an exercise price of $4.45, were accelerated, fully vested, canceled, and converted into a cash payment.
• The cash payment for options was calculated as the aggregate number of shares underlying the option multiplied by the difference between the $11.00 Offer Price and the option's per share exercise price.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person and former shareholders, as the transactions represent a successful liquidity event and a cash payout resulting from the merger. The company itself transitioned to a private entity, which is a neutral outcome from a public market perspective.

Positives

• The reporting person received cash for her common stock and a significant cash payout from the acceleration and cash-out of her vested stock options.
• Evoke Pharma shareholders received a cash payment of $11.00 per share, providing liquidity and a premium for their investment.

Negatives

• Evoke Pharma Inc. is no longer an independent publicly traded company, having become a wholly-owned subsidiary of QOL Medical, LLC.

Future Outlook

This filing reports a completed transaction and does not provide forward-looking statements or guidance for the now privately-held company.

Industry Context

This transaction represents a consolidation event within the pharmaceutical or medical sector, where a publicly traded company, Evoke Pharma, was acquired by a private entity, QOL Medical, LLC. Such acquisitions are common strategies for private equity or larger companies to expand their product portfolios, market share, or achieve operational synergies by integrating smaller, specialized firms.

Corporate Governance

Related Party Transactions

• The reported transactions involve an insider (Chief Medical Officer Marilyn R. Carlson) disposing of company securities in connection with a corporate acquisition, which is a standard type of related party transaction reporting for Form 4 filings.

Stakeholder Impact

• Shareholders of Evoke Pharma Inc. received a cash payment of $11.00 per share, providing a clear liquidity event for their investment.
• Employees holding stock options, such as the reporting person, had their options accelerated, vested, and cashed out, providing a financial benefit.
• Evoke Pharma as a corporate entity is now a wholly-owned subsidiary, which will impact its operational autonomy and strategic direction, now determined by QOL Medical, LLC.

Key Dates

Keywords

Evoke Pharma, EVOK, QOL Medical, Merger, Acquisition, Tender Offer, Insider Transaction, Form 4, Stock Options, Chief Medical Officer